KALETRA 133.3mg/33.3mg Price

Overview

Welcome to Dwaey, specifically on KALETRA 133.3mg/33.3mg page.
This medicine contains an important and useful components, as it consists of
Lopinavir, Ritonaviris available in the market in concentration

Name

Ritonavir + Lopinavir

Precaution

Pancreatitis, hepatic impairment, haemophilia. Pregnancy, lactation, elderly, child <6 mth. Lactation: unknown if distributed in breast milk; HIV+ women shouldn't breastfeed anyway

Indication

HIV infection

Contra indication

Hypersensitivity. Avoid concomitant use with ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine), cisapride, pimozide, and sedatives (midazolam, triazolam).

Side Effect

>10% Diarrhea (7-9%),Hyperlipidemia (3-39%),Nausea (5-16%),Rash (12%),Abdominal pain (1-11%),Nausea (5-16%),ALT increased (1-11%) 1-10% (selected) Headache (2-6%),Elevated LFTs (2-10%),Weakness (< 9%),Hyperuricemia (< 5%),Flatulence (1-4%),Neutropenia (1-5%) <1% Stevens Johnson Syndrome,Erythema multiforme,Toxic epidermal necrolysis

Pregnancy Category ID

3

Mode of Action

Lopinavir inhibits HIV protease, causing the enzyme incapable of processing the polyprotein precursor. This leads to the production of non-infectious and immature HIV particles. Ritonavir, a selectively competitive reversible inhibitor of HIV protease, interferes with the formation of essential proteins and enzymes. After which, the formation of immature and non-infectious viruses follows. It also interferes with the production of infectious HIV and limits further infectious spread of the virus.

Interaction

Ritonvir ....Decreased plasma conc with phenobarbital, carbamazepine, dexamethasone, phenytoin, rifabutin and rifampicn. Increased plasma conc of certain drugs highly metabolized by CYP3A. May increase serum levels of sildenafil. Potentially Fatal: Avoid concurrent admin of oral solution (contains alcohol) with disulfiram or metronidazole. Increased risk of myopathy when used with simvastatin or lovastatin. Concurrent use with alfuzosin may lead to serious hypotension. Increased risk of cardiac arrhythmias when used with amiodarone, cisapride, propafenone, quinidine, flecainide and pimozide. Risk of acute ergot toxicity when used with ergot derivatives. Increased risk of serious adverse reactions when used with midazolam or triazolam. Lopinavir....Most interactions reported with lopinavir are due to its combination with the potent inhibitor of CYP3A4 ritonavir. Lopinavir levels may be decreased by CYP3A4 inducers such as efavirenz, nevirapine, amprenavir, nelfinavir, rifampicin, phenytoin. Lopinavir level are increased by CYP3A4 inhibitors such as valproate and rifabutin. Potentially Fatal: Severe myelosuppression reported with paclitaxel.

Pregnancy Category Note

Information not available

Adult Dose

Child Dose

Renal Dose

Administration